8/28/15 Contest update
Reading the Scientific American issue devoted to Albert Einstein the other day, I came across this paragraph: “Albert Einstein once said that there are only two things that might be infinite: the universe and human stupidity. And he wasn’t sure about the universe.”
Was it merely coincidence that I saw Einstein’s remark just after seeing the latest presidential election poll results?
Speaking of human stupidity, the stock market has lately been doing its best to make investors feel stupid. Nonetheless, when Friday’s closing bell rang, both biotechs and the general market actually wound up with gains for the week.
At Friday’s close, the Contest median was up 24.08% YTD (vs. up 18.79% YTD a week ago), the Nasdaq Biotech Index was up 16.27% YTD (vs. up 12.14% YTD a week ago), while the smaller-cap S&P Biotechnology Select Industry Index was up 22.92% YTD (vs. up 16.45% YTD a week ago). The Nasdaq Composite Index was up 1.95% YTD (vs. down -.63% YTD a week ago).
DANIEL’S portfolio, up 86.17% YTD, held on to the Contest lead (see below for merger-related portfolio adjustments). But, boosted by an ARIA buyout offer, second place MOPGCW’s portfolio, up 82.15% YTD, is closing in. GUERL’s portfolio, up 63.15% YTD, remained in third place.
At the week’s close, 44 of the 51 Contest portfolios were in the black with 33 beating the NBI and 27 beating the SPSIBI. The 206 Contest stock picks have an average YTD gain of 16.24% and a much reduced median YTD gain of 1.06%.
Below is the Top Ten list. Also below are the week’s Top 5 & Bottom 5 Stocks. (Foreign stock prices are not converted to US$ in these Tables.)
Portfolio adjustments: The table I’ve posted below my usual update tables shows the number of shares added to DANIEL’s portfolio as a result of the TRGT/CBIO merger. The complex merger resulted in a cash distribution of $6,270.72 to DANIEL’s portfolio. I calculated the number of additional shares by using the initial percentages allocated to the eight stocks in the portfolio (including TRGT*); multiplied each stock’s percentage by $6,270.72; then divided the allocated cash for each stock by its 8/28 closing price.
For example, BOTA was allocated 10% in the initial portfolio; 10% of $6,270.72 is $627.07; $627.07 divided by BOTA’s closing price of $2.08 adds 301.48 shares to DANIEL’s portfolio.
*Note that I initially didn’t plan to allocate any cash to CBIO, but changed my mind as it seems to make more sense to do so. I highly doubt, however, either choice will make a significant difference in the Contest outcome.
(For those interested, my method for calculating the portfolio profit/loss resulting from additional shares is to simply treat the additional shares as a separate portfolio. I then add its profit/loss to the original portfolio profit/loss to get the total portfolio profit/loss. I use the separate portfolio method as it’s less work to do it that way, given how my spreadsheets and macros are set up.)
(All corrections, especially adjustments for buyouts & splits, greatly appreciated.)
Have a relaxing weekend biotechies!
Peace & good health,
Bulba
8/28/15
Rank Name Profit/Loss
1 DANIEL 86,166
2 MOPGCW 82,147
3 GUERL 63,150
4 DONS 60,310
5 DEWDIL 59,404
6 MCBIO 55,096
7 GHMM 52,291
8 IJF 49,326
9 OLIVIER 48,523
10 CLARK 44,381
Week's Top 5 Gainers
Symbol 8/21/15 8/28/15 Wk.%chg.
STXS 0.758 1.800 137.47%
ARIA 6.630 9.890 49.17%
EGRX 65.450 83.670 27.84%
EKSO 1.100 1.370 24.55%
SZYM 2.100 2.520 20.00%
Week's Worst 5 Losers
Symbol 8/21/15 8/28/15 Wk.%chg.
VTL 17.680 3.410 -80.71%
MCUR 4.500 3.220 -28.44%
OMER 20.960 15.500 -26.05%
ENUM 0.650 0.520 -20.00%
SKBI 1.430 1.170 -18.18%
Added Shares to DANIEL’s Portfolio from TRGT/CBIO merger
$ all. 8/28pr. shrs.
BOTA 627.07 2.08 301.48
CBIO 627.07 9.00 69.67
DARA 940.61 0.86 1093.73
ECYT 1097.38 5.28 207.84
OGXI 627.07 2.68 233.98
REPH 1254.14 14.09 89.01
ROSG 313.54 2.45 127.97
TBRA 783.84 13.62 57.55
6,270.72 |
